MOSAIC - Vaccine Naïve Group 3
The population is composed of individuals 18 years of age or older, in good health or with mild or moderate stable co-morbidities, who have not received an authorized COVID-19 vaccine at any time, and will receive one dose (0,20 mg/mL) of Moderna vaccine via intramuscular injection in the deltoid muscle followed by one dose (0,3mL) of Pfizer/BioNTech vaccine after 28 days.
The population is composed of individuals 18 years of age or older, in good health or with mild or moderate stable co-morbidities, who have not received an authorized COVID-19 vaccine at any time, and will receive one dose (0,20 mg/mL) of Moderna vaccine via intramuscular injection in the deltoid muscle followed by one dose (0,3mL) of Pfizer/BioNTech vaccine after 28 days.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
-
Ethnic Origin
-
-
Health Status
-
Inclusion: - In good health or with mild or moderate stable co-morbidities.
Exclusion: - Any confirmed or suspected immunosuppressive or immunodeficient state
- Asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids
- Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin)
- Bleeding disorder or history of significant bleeding following IM injections or venipuncture
- History of laboratory-confirmed COVID-19 disease prior to enrolment.
-
Other Criteria
-
Inclusion: - Have not received an authorized COVID-19 vaccine at any time
- If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine.
Exclusion: - Administration of immunoglobulins and/or any blood products within 3 months,
- Allergy to any study vaccine or any active substance,
- Continuous use of anticoagulants,
- Pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine.
-
Supplementary Information about selection criteria
-
Participants will be recruited from the communities in which CTN study sites are situated; these are urban centres in Canada. Enrolment will be open to persons of all genders and ethnicities.
-
Sources of recruitment
-
-
General Population
-
-
Supplementary Information
-
Participants were recruited using social media, media outlets, print and electronic media at vaccination centers, and by contacting persons on existing databases at each site.
-
Number of Participants
-
-
Number of Participants with Biological Samples
-